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Abstract 
 Since cardiovascular diseases are the leading cause of death worldwide and the 
mammalian adult heart is incapable of consistent regeneration, countless studies have been 
performed to characterize the heart injury-response in order to develop new therapeutic 
alternatives to improve cardiac repair. 
 In 2011, a proof-of-principle study by Porrello et al., demonstrated that in a 
restricted time-window after birth murine hearts were able to fully regenerate after apex 
resection without scar formation. However, when the same injury procedure was performed 
after post-natal day 7, it results in a reparative response characterized by formation of a 
fibrotic scar. This work, which constituted a breakthrough in the field, was recently refuted 
by Anderson et al., whom reported no signs of cardiac regeneration in the first week of post-
natal life, setting controversy on the cardiovascular field. 
 Our work aims to clarify the type of response triggered following neonatal apex 
resection by detailed analysis of histological/cellular/extracellular matrix (ECM) changes 
activated after injury. Additionally, a deeper assessment of the neomyogenic potential after 
injury was performed. 
 Fine histological analysis of resected hearts show that, despite the proportion of 
affected tissue is significantly diminished throughout time, only partial recovery is observed 
60 days post-resection (dpr) as interstitial scar-tissue is formed in the myocardium. However, 
systolic heart function was fully restored at 21dpr and no signs of cardiomyocyte (CM) 
hypertrophy nor compromised vascularization were detected 60 dpr. Furthermore, the 
neonatal heart response to injury involves the recruitment of inflammatory cells, activation 
of fibroblasts, and ECM remodeling, namely fibronectin and tenascin-C. 
 Hereby, we propose a model of neonatal cardiac injury-response that encompasses 
microenvironmental alterations as main drivers of both reparative and regenerative 
mechanisms, culminating in the formation of newly formed myocardial tissue with interstitial 
fibrosis and undetectable impact on systolic function.  
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Resumo 
 As doenças cardiovasculares são a principal causa de morte à escala mundial em parte 
devido ao facto do coração de mamíferos na vida adulta ser desprovido de capacidade 
regenerativa. Nesse sentido, numerosos estudos têm caracterizado a resposta à lesão em 
busca de sinais moleculares para integrar novos tratamentos para restaurar a função do 
miocárdio danificado. 
 Em 2011, um estudo de prova de princípio demonstrou que, na primeira semana de 
vida, os corações de murganho são capazes de regenerar na totalidade, sem formação de 
tecido cicatricial, após remoção do ápice. No entanto, depois do sétimo dia de vida, os 
corações respondem à lesão de forma diferente e desenvolvem fibrose, produzindo um efeito 
deletério na função sistólica. Todavia, em 2014, este modelo foi refutado por Andersen et al., 
o qual reportou que, após a sua replicação, não se observou qualquer recuperação do 
miocárdio durante a primeira semana de vida pós-natal. Esta publicação estabeleceu 
controvérsia em torno da existência de regeneração cardíaca em mamíferos e até hoje não 
existe um consenso entre a comunidade cardiovascular. Posto isto, esta dissertação visa 
caraterizar mais aprofundadamente a resposta de murganhos neonatais à resseção do ápice 
cardíaco estudando a dinâmica celular e extracelular ativada após lesão. 
 Os nossos resultados mostram que os corações não recuperam totalmente até 60 dias 
após lesão, ainda que ao longo do tempo a lesão (área afetada pela fibrose) vá ficando menos 
representativa e se verifique restabelecimento da função (21 dias) e neovascularização (60 
dias), sem evidência de hipertrofia de cardiomiócitos. 
 Sumariamente, a resposta neonatal à lesão envolve o recrutamento de células 
inflamatórias, ativação de fibroblastos, produção e reorganização de matriz extracelular e 
restabelecimento da vascularização. Os nossos dados apontam ainda para que haja uma 
recuperação do tecido removido via proliferação de cardiomiócitos residentes. 
 Em suma os nossos resultados mostram que o coração de murganho ativa eficazmente 
mecanismos regenerativos que são responsáveis pela recuperação parcial do coração. Contudo 
estes revelam-se insuficientes e, através de mecanismos reparativos, uma cicatriz fibrótica é 
gerada. 
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Chapter 1 
Introduction 
 Cardiovascular diseases are the leading cause of death and disability in the modern 
World, counting with nearly 17 million deaths according to annual estimates, which 
corresponds to 30% of global mortality. Indeed, among non-transmissible diseases, 
cardiovascular diseases are the most lethal, a tendency that has been observed for decades 
and is predicted to continue [1-3]. Considering the severe socio-economic impact of these 
estimates, the development of new preventive strategies and therapies is a public health 
priority [4]. Ischemic heart disease (also known as coronary heart disease), responsible for 
over 43% of cardiovascular-related deaths, is characterized by the deposition of 
atherosclerotic plaques in coronary arteries that progressively obstruct their lumen, thereby 
decreasing blood supply to the heart. This event commonly leads to acute myocardial 
infarction (AMI) as the result of diminished oxygenation of heart muscle, inducing massive 
cell death and inflammation [5]. Afterwards, as adult cardiomyocytes (CM) (the contractile 
unit of the heart) do not proliferate in a sustainable manner, the heart engages on a 
reparative response towards the damaged tissue replacement by a non-functional fibrotic 
scar. The combination of muscle loss with the development of myocardial fibrosis, which 
hampers cardiomyocytic contraction and induces CM hypertrophy, ultimately leads to heart 
failure [6, 7].  Looking forward to develop efficient therapies for heart failure, 
cardiovascular research has been fostering studies on the identification of regenerative cues 
through dissection of evolutionarily conserved heart-injury mechanisms and of heart 
development.  
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1.1 - Cardiac Regeneration In Mammals: Opening New 
Avenues For Therapeutic Alternatives 
 Regeneration is defined as the complete restoration of lost/damaged tissue both at 
the histological and functional level. Regeneration is commonly accomplished by cellular 
proliferation, recapitulating, to a limited extent, the embryonic program that gave rise to 
the original tissue [8]. In opposition, repair consists in the robust activation of fibrogenic 
mechanisms to provide tissue structural support by increased production of collagen, which in 
turn, leads to the formation of a fibrotic scar. Tissue repair is insufficient for effective and 
permanent re-establishment of tissue histo-functional integrity. The mammalian healing 
response fluctuates between these two types of response, depending on the tissue-specific 
stem-cell pool and in the extent of injury. In the case of the adult heart, in contrast with 
other systems (e.g. intestine, hematopoietic system, skin), the injury response involves 
mainly reparative mechanisms. 
Until the past century the heart was considered a non-regenerative organ, as CMs were 
thought to enter, shortly after birth, in a non-reversible post-mitotic state with no 
proliferative capacity [9]. However in the early 2000s, this paradigm changed with reports of 
progenitor-like cells resident in the adult heart and low-rate CM renewal throughout life 
(detailed on section 1.2). The first signs of CM proliferation came from AMI injured hearts, in 
which the border and remote zone exhibits 70 and 24 times more proliferation, respectively, 
comparing to normal hearts [10]. Bergman et al. also reported CM turnover at a rate of 
approximately 1% at the age of 25, diminishing to approximately 0.45% at the age of 75. 
Accordingly, even though 50% of CMs are replaced during the normal lifespan, this renewal is 
clearly insufficient to re-establish the myocardium following cardiac injury, in which nearly 
25% of CMs are lost [11-14]. 
On the other hand, several resident populations of cardiac progenitor cells (CPCs) have 
been identified in the adult heart. CPCs have been identified by the expression of specific 
surface markers like c-kit [15], stem cell antigen 1 (Sca1) [16], Isl1 [17] and platelet derived 
growth factor receptor α (PDGFRα) [18], as well as by multiple physiologic properties and 
colony formation ability [19]. Moreover, efforts have been made to unequivocally identify and 
validate adult cardiac stem/progenitor populations, and above all, to clarify their ability to 
generate CMs [12, 20]. Activation of CPCs was reported in situ, through different approaches 
based on microRNA regulators [21, 22], administration of growth factors [23] and 
pharmacological agents [24]. Importantly, these cells have been isolated and expanded in 
vitro and subsequently injected in the AMI patients, leading to the reduction of the infarction 
size; however, long-term effect of cell delivery in a large trial is yet to be performed [25] 
although phase I clinical trials had been successfully concluded [26]. Overall the present 
perspective on the field is that CPCs have limited capacity to generate new CMs and their 
protective effect is mainly mediated by paracrine mechanisms that improve angiogenesis and 
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cell survival upon AMI [27]. Therefore, despite of being activated upon injury, it is consensual 
that CPC potential is limited and that their turnover is not sufficient to restore the damaged 
myocardium [20, 28]. 
 The prospect of endogenous regenerative potential of the adult heart, either by the 
activation of a progenitor-cell pool or by cell-cycle re-enter of pre-existent CMs, opens new 
avenues for therapeutic exploitation. Although the reported potential is extensively limited, 
the question that remains is whether it could be activated by correct environmental signals. 
Hereupon, cardiovascular field has attracted specialists in stem cell/developmental biology, 
biomaterials and tissue engineering, whom primary objective is the development of strategies 
to improve myocardial restoration following injury. In fact, activation of endogenous CPCs, 
reprogramming of cardiac fibroblasts in CMs and recruitment of non-resident stem cells, in 
combination with advanced tissue engineering approaches to develop cardiac 
functional/regenerative patches, are amongst most frequent reported applications [19, 29]. 
 Notwithstanding the reported endogenous regenerative potential of the adult 
mammalian heart, these mechanisms are clearly insufficient and, in pathological situations, 
reparative mechanisms are preponderant. Hence, in the quest for novel therapeutic 
alternatives, cardiovascular research has been fostering the study of heart throughout 
ontogeny, aiming at unveiling mechanisms of heart morphogenesis which can be further 
employed in the improvement of adult heart repair. In addition, as other organ-systems 
display enhanced capacity to regenerate at early ontogenic stages [30], as is the case of the 
skin, the same was postulated for the heart. Indeed, the first reference to a developmental 
window for heart regeneration in mammals was provided by Timothy C. Cox and colleagues in 
2008. In this study, using a conditional knockout for an enzyme essential in the energetic 
metabolism of CMs, the authors reported that heterozygous embryos were able to recover 
from 50% of Hccs (holocytochrome c synthase) deficient cardiac cells at midgestation to 10% 
at birth. Compensatory increase in the proliferation of healthy cells was shown to mediate 
the regenerative response that gave rise to a fully functional heart at birth [31]. In 2011, 
Porrello and colleagues showed, using the murine model, the existence of a time-window in 
which mammalian cardiac regeneration could occur. In fact, 1-day-old (P1) mice were able to 
histo-functionally restore the heart following apex resection whereas at P7, this capacity is 
already lost and extensive fibrosis is observed [32]. Enthusiastically, these findings were 
corroborated by others, even when different injury models such as AMI, through left anterior 
descending coronary artery (LAD) ligation [33-35], and cryoinjury [36] were applied. Indeed, 
in all reported injury-models the restoration of the damaged myocardium is achieved by 
formation of a blood clot that covered and sealed the injury site, development of an 
inflammatory response and activation of neovascularisation and neomyogenesis [38]. These 
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experiments showed that the de novo tissue formation is not dependent on CPCs as new CMs 
arise from pre-existent ones that undergo dedifferentiation and cell-cycle re-entry [35]. 
Although neonatal cardiac injury models currently available do not reproduce entirely the 
adult heart physiopathology, the establishment of these models propelled new insight about 
regenerative mechanisms underlying cardiac injury. Indeed, these models have become a 
solid platform for the study of mechanisms that contribute to the loss of cardiac regenerative 
ability from P7 onwards (detailed on section 1.2).  
 However, in 2014, neonatal heart regeneration has been refuted by Anderson et al, 
whom reported no signs of cardiac regeneration in the first week of post-natal life, creating 
controversy in the field [39, 40]. In opposition to the pioneer work, these authors 
documented a strong inflammatory response in the injury site, followed by massive collagen 
deposition. Additionally, resected hearts were shown to be smaller than the respective 
surgical controls, displaying impaired neovascularization and cardiomyocyte proliferation. 
Importantly, the authors reported similar results in C57BL/6 and in ICR/CD1 mice strains, 
indicative that murine cardiac response to apex resection is not strain-specific. The authors 
explained the discrepancies between laboratories to the less detailed histological analysis of 
the initial paper which could originate underrepresentation of fibrotic lesions. This deceptive 
outcome has created uncertainties concerning the reproducibility of the neonatal injury 
model and on the ability of neonates to indeed regenerate their hearts. Nevertheless, it was 
recently reported that there is a close relationship between the extension of the injury and 
the outcome of the healing response, which may explain the different results across 
laboratories [38, 41]. An independent letter led by Kotlikoff remarked that, despite some 
evident parallelism between Andersen et al. findings and their report on neonatal cryoinjury 
(i.e. CD45+ cell influx, fibrosis and neovascularization of the ablated myocardium) [34], a 
critical point is missing in Andersen’s paper, namely that neomyogenesis is a central feature 
in neonatal heart repair [42]. Andersen and colleagues counter-argument has been that in 
their experimental setting, neonatal hearts healed from apex resections with profound 
scarring and minimal neomyogenesis, therefore lacking substantial regenerative capacity 
[40]. 
 
1.2 - An Integrative Perspective On The Bounderies Of 
Heart Regeneration In Mammals  
 The aforementioned studies, together with evidences from other organ-systems [43], 
are indicative that the capacity to regenerate is dimmed throughout ontogeny. Hence, 
although the fetus is endowed with cell-plasticity and capability of functional 
reestablishment following injury, this capacity is lost throughout the postnatal period (the 
case of the heart) and/or with aging. The study of the heart injury-response throughout 
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development and post-birth may unveil the mechanisms restricting cardiac regenerative 
capacity during adulthood, which is of high relevance, considering that their silencing may 
improve heart repair (detailed in section 1.2.1). 
 Interestingly, when cardiac regenerative capacity is analysed throughout the 
evolutionary axis, the mammalian specification is inversely correlated with heart 
regenerative capacity [44]. Unlike mammals, adult amphibians and fish (namely zebrafish) 
are capable of cardiac regeneration [45, 46], In line with this, several studies have dissected 
the mechanisms underlying the cardiac regenerative response of lower vertebrate, aiming at 
identifying signals/mechanisms of translational relevance [47]. In fact, the identification of 
mammals and low vertebrates dissimilarities may elucidate the physiological basis for the 
limited capacity of the mammalian heart (in detail in section 1.2.2) 
 
1.2.1. Cardiac regenerative capacity throughout ontogeny 
 
 After parturition, mammalian hearts undergo dramatic alterations that dictate the 
transition from hyperplasic to hypertrophic growth [48] (Figure 1). Yet, the stimuli that 
induce CM phenotypic transition are not well understood. Neonatal CMs tend to be smaller in 
size, contain fewer myofibrils and be mononucleated when compared to adult ones, which 
may ease their cell-cycle re-rentry [29]. Similarly, during embryogenesis, mammalian hearts 
develop at expenses of a highly proliferative population of mononucleated CMs that present 
little organized sarcomeres [49, 50]. Post-birth, most CMs undergo DNA duplication without 
cytokinesis. Hence, in rodents, CMs undergo mitosis without cytokinesis and CMs become 
binucleated cells (around 80-90%) with diploid nucleus [14, 51]. In turn, humans CMs undergo 
mitosis without nuclear division and, therefore, the majority is mononucleated and own a 
polyploid nucleus [52]. 
 Additionally, mammals face a dramatic environmental shift in the transition between 
in utero and ex utero living. Adult zebrafish and fetal mammalian hearts are subjected to low 
oxygen levels whereas neonatal and adult mammals face an oxygen-rich environment. This 
has a severe impact over the metabolic status of CMs once while adult zebrafish and fetal 
mammalian CMs display anaerobic glucose-based metabolism and high proliferative capacity 
[53, 54], post-natal CMs generate their energy mainly through aerobic oxidative metabolism 
and the large majority have withdrawn from the cell-cycle [53, 55, 56]. Although 
mitochondrial oxidative phosphorylation is a more advantageous metabolic pathway, it 
implies the increase of reactive oxygen species (ROS). Recently, the increase of ROS during 
the first week of life and consequent activation of DNA damage response pathways has been 
proposed as a trigger for CM cell-cycle arrest [53]. 
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 Interestingly, CM phenotypic shift is accompanied by down-regulation of cell cycle 
factors and up-regulation of cell cycle inhibitors [57]. The mammalian cell cycle is tightly 
regulated by cell cycle machinery, combining positive and negative regulators [58]. In line 
with this, adult-heart growth is essentially achieved by CM hypertrophy rather than CM 
hyperplasia [59]. In adult mammalian CM, cyclin-dependent kinase/cyclin complex, Myc, E2F 
transcription factors, cell cycle activators, were demonstrated to be repressed whereas p21, 
p27, retinoblastoma protein, and cyclin-dependent kinase inhibitors, negative cell cycle 
regulators, are overexpressed [60-62]. Pasumarthi et al. demonstrated that cyclin D2 
expression induces permanent DNA synthesis, reducing fibrosis after AMI [60]. Hence, 
manipulation of CM cycle activity is a promising strategy to enhance myocardium 
repopulation following injury. Furthermore, dynamic alterations in DNA methylation were 
shown to modulate CM phenotype. Upon birth, developmental signalling pathways as well as 
cell cycle regulator genes are silenced through hypermethylation [63-65]. 
 Recapitulation of developmental signalling pathways in differentiated CMs appears to 
be another promising strategy to induce CM proliferation. Neuregulin and its receptors, ErbB2 
and ErbB4, are involved in cardiac development by promoting CM proliferation and 
differentiation [66]. In fact, neuregulin and oncostatin administration, an extracellular factor 
responsible for the activation of neuregulin receptors, were reported to stimulate CM 
proliferation in physiologic and pathologic scenarios [67-69]. In line with this, other 
developmental signalling pathways involved in CM cell cycle re-entry (e.g. Hippo and Wnt) 
have also been targeted [70-73]. Moreover, inhibition of p38α MAPK (negative regulator of CM 
proliferation in mammals), together with fibroblast growth factor 1 (FGF1) (capable of 
inducing CMs dedifferentiation) [74, 75], was reported to induce CM proliferation following 
AMI while contributing to fibrosis and infarct size reduction and increased angiogenesis [76]. 
Curiously, these mitogenic factors seem to stimulate exclusively mononucleated CMs [69]. 
 The role of microRNAs has also been under tight scrutiny during the postnatal 
regenerative time-window. Recently, more than 40 microRNAs have been identified as 
mitotic triggers for CM although deeper studies are required in order to manipulate them for 
future therapies [77, 78]. For example, after birth, overexpression of miR-15 family is 
observed in murine hearts which coincides with the loss of CM proliferative capacity [35]. 
Interestingly, miR-19 (a member of mir-15 family) overexpression inhibits neonatal heart 
regeneration [35].  
 Furthermore, extracellular matrix (ECM) also effectively modulates cell behaviour 
either via cell-matrix interactions, paracrine factors incorporated within the network and by 
molecular and mechanistic properties of ECM [79]. Numerous studies have shown that cells 
are responsive to the microenvironment and, since there is a shift on ECM properties 
throughout development, this structure may instruct cells in an ontogenetic-dependent 
manner and impact on the regenerative capacity [80, 81]. In physiological conditions, the 
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myocardium is gradually enriched in collagen type I, which becomes the most predominant 
cardiac ECM protein in the adulthood, whereas fibronectin (Fn) and elastin become increasing 
less represented. These composition changes strongly increase ventricular stiffness, 
contrasting with the cardiac regenerative potential that follows the opposite trend [82]. 
 
Figure 1. Schematic differences between fetal and post-natal CMs. After birth, mammalian hearts 
undergo dramatic alterations that dictate the transition from hyperplasic to hypertrophic growth, which 
is accompanied by metabolic, morphologic and gene expression modifications [83]. 
 
 
1.2.2. Phylogenetic axis of cardiac regeneration 
 
 Owing to increased energetic requirements, mammals have developed different 
mechanisms at the anatomic, histological and biochemical level that are inversely correlated 
with heart regenerative capacity [44] (Figure 2). In fact, throughout vertebrate evolution a 
specialized electrical conduction system, where the transmission of electromechanical 
stimulus is achieved through gap junctions, was developed. More than 20 different connexin 
family members are found in mammals, allowing rapid and synchronous contractions. In 
agreement, an altered expression and distribution of connexin-43 (Cx43), a structural protein 
of gap junctions, is correlated to the development of cardiomyopathies, such as hypertrophy 
and ischemia [84-87]. 
 Mammals have developed higher blood pressure when compared with adult zebrafish. 
In an injury scenario, zebrafish are able to quickly seal the wounded area with a blood clot 
while CMs dedifferentiate, disassemble their sarcomeric structure and detach from one 
another [88, 89]. In opposition, due to increased blood-pressure levels, the mammalian heart 
requires a higher structural support to counteract bleeding, thus favouring scarring [83]. 
 The inflammatory response has been also suggested to be a key player in 
regeneration [90] since it is required for removal of cell debris, recruitment other cell types, 
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via soluble factor release, and to promote the formation of a transitional matrix that seals 
the injured area. However, prolonged inflammation limits tissue expansion of the injured 
area by an excessive ECM deposition that hampers cardiomyocytic survival [90]. Apart from 
an innate immune system, lower vertebrates present an incomplete adaptive immunity, 
which largely differs from mice that develops this system around birth or even from humans 
where the adaptive immunity is already present at gestational week 10 [91, 92]. Several 
studies have correlated the loss of immune tolerance with a restricted regenerative capacity 
[93-96]. More recently, postnatal changes in murine immune system corroborated this 
premise. Different molecular signatures were identified in monocytes and macrophages from 
regenerative (P1) and reparative (P14) periods following AMI. Indeed, P1 macrophages 
express pro-angiogenic cytokines, which are crucial for a successful tissue restoration. 
Interestingly, depletion of macrophages in neonatal regenerative period led to of the loss of 
the regenerative capacity, implicating the immune response as major player on cardiac 
regeneration [97, 98]. 
 Considering the extracellular environment, several ECM proteins are required for 
efficient zebrafish heart regeneration. Indeed, apex-resection promotes the formation of a 
provisional fibrin/Fn-rich matrix that allows CM migration to the injury site. Fn was shown to 
be extensively deposited at the injury site by epicardial cells and its relevance became 
undeniable once its deletion impaired cardiac regeneration [99]. In adult newts hyaluronic 
acid, Fn and tenascin-C (Tn-C) are also deposited following apex resection, and deposition of 
Tn-C was shown to be sufficient to induce CM proliferation [100]. Contrasting with fish and 
amphibians that own a soft ECM throughout life and during injury response, mammals exhibit 
exacerbated production of collagen type I and III, as well as fibre rearrangement following 
injury. The increased crosslink between ECM components leads to the escalation of 
myocardial elastic modulus [81], which limits cellular movement [101] and is on the origin of 
cardiac dysfunction [102]. Distinct reports have shown that fibroblast distribution is different 
between lower and higher vertebrates. In mammals, fibroblasts are one of the most 
represented cell types while, in lower vertebrates, they are less frequent and dispersed in 
the myocardium [103]. Not surprisingly, an extensive and well-organized cardiac fibroblast 
structure in mammals is suggested to have deleterious impact on regeneration [103] once 
they are not only responsible for scar formation but also for triggering CM cell cycle 
withdrawal [104]. 
 Importantly, a pattern of biological events is transversal to all vertebrates. Firstly, a 
blood clot is formed at the injury site that seals the lumen and induces an early and strong 
inflammatory response. Gradually, the blood clot and fibrotic tissue are replaced by novel 
CMs arising from pre-existing ones. Fibroblast recruitment, extracellular matrix deposition 
and epicardial genes activation are other hallmarks of heart regenerative response of low 
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vertebrates [105] which are yet to be explored in mammals and will partially be addressed in 
this dissertation (Chapter 2 and 5). 
  
 
 
Figure 2. Heart anatomy and regenerative potential throughout the phylogenetic axis. Within 
vertebrates, the heart exhibits anatomic and physiologic variability owing to adaptation to distinct 
environments. The multiple mechanisms acquired during evolution are inversely correlated with heart 
regenerative capacity [44]. 
1.3 - Role of Fibroblasts in Cardiac Injury Response 
 Scarring is a major obstacle to the functional recovery of the injured mammalian 
heart. It is widely recognized that cardiac fibroblasts are critically involved in the reparative 
response following myocardial infarction and in cardiac ECM remodeling, depositing large 
amounts of collagen [103]. Even still, the specific contribution of non-myocardial cardiac 
cells and extracellular matrix (ECM) in neonatal regenerative cardiac response is yet to be 
determined. 
 Among cardiac cellular compartment in the adult heart, cardiac fibroblasts are the 
most predominant ones, accounting for almost two thirds of the myocardial cells [106]. They 
are the main producers of ECM, synthesizing Fn (most abundant non collagenous protein), 
vitronectin, collagen types I, III and V among other ECM proteins in different proportions [80, 
107]. In homeostatic conditions, fibroblasts provide mechanical support for CMs, modulate 
heart conduction system and transmit the contractile force [108, 109]. 
 Apart from a structural role, in development, fibroblasts interact with CMs through 
paracrine factors and cell-cell interactions. Thus, the latter are able to mediate CM 
 10  Introduction 
10 
proliferation via Fn/β1-integrin-mediated pathway and by production of collagen and 
heparin-binding EGF-like growth factor [104]. Within the first two weeks of life there is a 
massive increase on cardiac fibroblast population, in a period coincident with the loss of 
neonatal regenerative capacity [109]. 
 Unsurprisingly, cardiac fibroblasts are mainly recognized by their activation upon MI. 
Initially, a rapid inflammatory response is triggered by a massive cell death, where immune 
cells are recruited by factors released by the necrotic/apoptotic cells and by inflammatory 
cells [110]. Inflammation resolution induces differentiation of fibroblasts into myofibroblasts 
[111, 112]. Finally, myofibroblasts and resident fibroblasts deposit large amounts of ECM 
proteins mainly collagen type I and III, emerging a non-functional fibrotic scar [113]. 
Additionally, fibroblasts are able to modulate angiogenesis, instruct neighbouring CMs and 
regulate matrix remodelling through expression of proteolytic enzymes (e.g matrix 
metalloproteinases (MMPs)) and their inhibitors (e.g tissue inhibitor metalloproteinases 
(TIMPs)) [104, 109]. In this sense, modulation of fibroblast activity can impact the balance 
between regeneration versus reparative healing after cardiac injury and may constitute an 
important therapeutic target. 
 Frustratingly, the knowledge of this population has been hampered by the absence of 
reliable markers. Some efforts have been made to overcome this issue, namely by using some 
proteins to prospectively identify fibroblasts. Vimentin and fibroblast specific protein (FSP1) 
have been widely used in this purpose but lack specificity since they can be expressed by 
endothelial and smooth muscle cells or by lymphocytes, monocytes and macrophages [111, 
114-116]. Additionally, CD90 (Thy 1) [117], transcription factor 21 (tcf-21) [118], discoidin 
receptor domain 2 (DDR 2) [119], periostin [120] have also been used. However, considering 
the heterogeneity this population of cells, results obtained from the usage of a single marker 
should be carefully interpreted. Additionally, the differentiation of fibroblasts into 
myofibroblasts, a hallmark in reparative response, is mainly detected by the expression of α-
smooth-muscle actin (α-SMA).  
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Chapter 2 
Preliminary Data 
 Cardiovascular community has been focused on investigating mechanisms that govern 
neonatal regeneration, aiming to extend this ability to later periods in life [32-36, 38]. 
However, in 2014, the regenerative capacity of neonatal mice has been questioned and, thus, 
a consensus on the field is yet to be reached [39, 40]. 
 The neonatal apex resection model has been established in our laboratory (Figure 3) 
using the same protocol described originally by Porrello et al. [32]. However, we performed 
the procedure on inbred C57BL/6 strain at P1.5 contrasting to the outbred ICR/CD-1 P1 mice 
used by Porrello et al.. Immediately after surgery, the survival rate is not significantly 
different between apex-resected animals (84.2%) and the surgical controls (86.5%). 
Notwithstanding, this value is considerably affected by maternal cannibalism in the first 48h 
post-surgery, lowering to approximately 48% and 67% for apex-resection and sham groups, 
respectively (Figure 4).  
 
 
Figure 3. Neonatal heart apex-resection injury model. The heart was assessed by opening the thorax 
in the 4th intercostal space and the apex was cut.  
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Figure 4.  Survival rate post-surgery. The survival rate to surgery in both group set on approximately 
85%. This value was considerably affected by maternal cannibalism during the first 48h post-surgery. 
Sham (n=52); Injury (n=38). 
 Twenty-one days after apex resection (dpr), animals do not show alterations on 
cardiac systolic function, as no differences were observed in ejection fraction and fraction 
shortening between resected and sham-operated animals (Figure 5). Although no differences 
were observed at the functional level, a small amount of myocardial fibrosis is noticeable at 
the resected area (Figure 6). 
 
 
 
Figure 5. Functional characterization of the neonatal cardiac injury model. No alterations in ejection 
fraction or fraction shortening were observed between groups in PSLAX and SAX views. Values are 
presented as means+ standard deviation (SD). 21d Sham (n=3), 21d Injury (n=4). 
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Figure 6. Histological characterization of the neonatal cardiac injury model. Masson’s Trichrome 
representative sections of apex-resected hearts at 0 and 21 dpr. Scale bar: 2mm. Higher power image 
(below) empathizes collagen deposition in apex region. Scale bar:1mm. 
 
 Additionally, extracellular and cellular dynamics following apex resection were 
assessed (Figure 7). Immediately after injury, disruption on the expression pattern of 
sarcomeric-α-actinin (s-α-actinin) and laminin is observed although partial recovery of the 
myocardium was detected at 21 dpr. Furthermore, the recruitment of inflammatory cells, 
ECM production and fibroblast activation are also involved in injury response. Hematopoietic 
cells (CD45 expressing cells) are present from 0 dpr and its frequency increases until  5dpr 
while, from this time-point onwards, a dramatic decrease of CD45-expressing cells is 
observed which may relate with the resolution of inflammation. Deposition of Fn and Tn-C, in 
the outer surface of the apex-resected area, is already evident at 48 hpr and remains 
elevated until 14 dpr for Fn and until 21 dpr for Tn-C. Differently, α-SMA and vimentin 
expressing cell rates steadily increase until 7 dpr, most likely representing the proliferation 
and differentiation of cardiac fibroblasts into myofibroblasts. The sham-operated animals 
were also evaluated for these processes; however, they maintained the myocardium structure 
throughout time with no significant signs of inflammation or fibrosis. 
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Figure 7. Representative images of cardiac cells co-localization with ECM components in the injury 
site at 0, 2, 5, 7, 14 and 21 days post-apex resection. The disruption of the myocardium caused by 
the apex resection is shown by a disorganized pattern of s-α-actinin and laminin until 14 days post apex 
resection. From 48 hours up to 21 days following apex resection the cellular and extracellular 
composition of the injured site is dramatically altered, culminating in the partial reestablishment of the 
removed myocardium at 21dpr. Scale-bars: 30 μm. n=3 
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 Given the activation of fibroblasts upon injury and aiming to dissect their role in 
regenerative/reparative mechanisms, a preliminary phenotypic characterization was 
performed throughout ontogeny. Cardiac fibroblasts were defined as CD90 expressing cells 
after exclusion of CD31 (endothelial marker), CD45 (hematopoietic marker) and TER119 
(erythrocytes marker) expressing cells. Briefly, the analysis shows an increase in the number 
of CD90 expressing cells among  development, which is in accordance with previous reports 
[109] (Figure 8 (A)). Moreover, we analyzed the expression of mesenchymal-associated 
markers and cell adhesion molecules within CD90+ population. Sca1 protein has been related 
with the identification of heart resident progenitors and Sca1+ cells has been implicated in 
the regenerative potential following AMI [121]. Notwithstanding, Sca-1 expression has been 
observed in the resident fibroblast population of several organs (e.g. skin and lungs) [20]. 
Finally, CD140a (also known as PDGFRα) is required for epicardial-specification through 
epithelial-to-mesenchymal transition in order to originate cardiac fibroblasts during 
development [122] and this marker has been reported to identify cardiac fibroblast subsets in 
the adulthood. We observed that CD90+CD140a+ and CD90+Sca-1+ fibroblast significantly 
increase post-birth, which accounts for the fact that fibroblast frequency in the heart is 
increased with age. As anticipated, we did not observe significant changes on the expression 
of CD44 throughout ontogeny since this molecule is associated to the differentiation of 
fibroblasts into myofibroblasts [123] and to fibroblast tissue-invasive capacity [124]. 
  Moreover, cardiac fibroblasts become the preponderant proliferative cells in 
adulthood, given the increment on Sca1 expressing cells (from residual at P2 to 70% in 
adulthood) (Figure 8 (B)). Within the proliferative compartment a phenotypic switch between 
the fetal and adult life could be detected. While at E17, the majority of proliferative cells 
are Sca-1- and CD90-, in the adult life the majority of the proliferative compartment 
expresses these markers.  
 Overall, our preliminary data is yet inconclusive regarding the activation of 
regenerative mechanisms and a deeper analysis is required to understand the mechanisms 
underlying neonatal cardiac injury response. 
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Figure 8. Phenotypic characterization of cardiac fibroblasts throughout ontogeny. (A) Within the 
stromal compartment i.e. CD45-CD31-TER119-, cardiac fibroblasts were identified by the expression of 
CD90 and the expression of mesenchymal-affiliated markers and adhesion molecules was further 
investigated. (B) Phenotypic characterization of proliferative stromal compartment throughout 
ontogeny. The proliferative stromal compartment was ascribed by Ki67 expression profile and it was 
further characterized E17 (n=6); P2 (n=11); P10 (n=11); P14 (n=11); Adult (n=4).  
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Chapter 3 
Aims 
 
Taking into account the controversy on the cardiovascular field and the preliminary work 
described above, the broader aims of the herein MSc dissertation are: (i) to clarify the type 
of response triggered following neonatal apex resection and to (ii) conclude whether this 
injury-model constitute a valid tool to study molecular mechanisms underlying cardiac 
regeneration. 
 
 To attain this major goals we will: 
 
 Follow-up the injury response for longer periods (60 days post-surgery); 
 Assess CM proliferation and CM hypertrophy by morphometric analysis; 
 Dissect ECM production and ECM-producing cells types during neonatal injury 
response; 
 Evaluate the activation of different cardiac fibroblast subsets upon injury. 
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Chapter 4 
Materials and Methods 
4.1 - Animals 
 All animal-testing procedures were subjected to approval by the IBMC-INEB (Instituto 
de Biologia Molecular e Celular– Instituto de Engenharia Biomédica) Animal Ethics Committee, 
and to the Direcção Geral de Veterinária (permit 022793), and are in conformity with the 
Directive 2010/63/EU of the European Parliament. Humane end-points were followed in 
accordance to the OECD Guidance Document on the Recognition, Assessment, and Use of 
Clinical Signs as Humane End points for Experimental Animals Used in Safety Evaluation. 
4.2 - Neonatal Murine Apex Resection Injury Model 
 The neonatal injury model consists in the apex surgical resection of post-natal day 
(P)1-1.5 C57BL/6 mice. The executed protocol was based in Porrello et al. experiments [32]. 
Animals were anesthetized by hypothermia during precisely three minutes to cease 
respiratory movements and heart contractions and lose the paw withdrawal reflex. Animals 
were immobilized with sealing tape in a lateral position, exposing the left-side flank. Then, 
the skin was cut and muscles disrupted until ribs were observed. The thoracic cavity was 
opened in the 4th intercostal space and the left ventricle apex cut with fine scissors. The 
thorax and skin were closed by 7-0 absorbable suture (Coated Vicryl Ethicon) and animals 
were recovered from anaesthesia under an infrared lamp together with stimulation by 
tightening the paw until regular breathing was observed. Once neonates are dependent on 
the mother for temperature regulation and nutrition, the operated animals were replaced on 
the progenitor cage. During all the procedure, except throughout surgery, neonates were 
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warmed by warming pads and infrared light. The surgical controls (sham-operated mice) 
underwent the same procedure in exception to cardiac manipulation. 
4.3 - Heart Fixation and Processing 
 Hearts were harvested at 0, 7 and 60 days post-surgery. Prior harvesting, animals 
were weighted and then hearts were carefully removed from the thoracic cavity, while 
surrounding tissues were cut with the assistance of a stereomicroscope. To assess injury 
extension, hearts were photographed and its vertical axis (comprised between the great 
vessels and apex) was measured using ImageJ software (v 2.0.0). 
 
4.4.1.  Gelatin Embedding 
 Tissue processing for cryosectioning involved 3 consecutive solution submersions 
where each of them lasted for 24 hours at 4⁰C. The first solution fixed the tissue and it is 
composed by: 0.2% paraformaldehyde in 0.12M phosphate buffer; the second of 4% sucrose in 
0.12M phosphate buffer, and the last one of 15% sucrose in 0.12M phosphate buffer. In the 
fourth step, hearts were incubated in 15% sucrose and 7.5% gelatin in 0.12M phosphate buffer 
during 1 hour at 37⁰C. Finally, hearts were transferred into a mold containing the latter 
warmed solution and placed into a recipient containing dry-ice-chilled 2-methylbutane (GPR 
Rectapur, VWR). Frozen hearts were stored at -80⁰C. For immunofluorescence, 7 day post-
surgery hearts were completely cut from the anterior to posterior side into 5 μm sections 
using a refrigerated microtome (Microtom HM 550, Thermo Scientific). 
 
4.4.2.  Paraffin Embedding 
 Before paraffin embedding, hearts were submersed in phosphate-buffered saline (PBS 
1x) and fixed in 10% formalin neutral buffer (VWR BDH & Prolabo) during 24 hours at room 
temperature. Then, hearts were processed during a total time of 12 hours in an automated 
system through successive PBS washes, crescent series of alcohols (Aga), Clear Rite 3® 
(Richard-Allan Scientific) and Shandon Histoplast (Thermo Scientific) at 56ºC. Finally, hearts 
were included in paraffin and sectioned longitudinally in 3 μm sections, using a microtome 
(RM2255, Leica). For representative sampling of the heart 10 series of cuts equally distanced 
were obtained. The distance between series was specific according to ontogenic stage: no 
sampling, 30 μm and 50 μm for 0, 21 and 60 days post-injury/sham hearts, respectively. 
 
Immunohistochemistry 
 21  
21 
 
4.4 - Histological Examination 
 Paraffin heart sections were dewaxed through three successive xylene solution 
submersions and then rehydrated by passing in a decrease series of ethanol solutions (100%, 
96%, 70% and 50%) prior to modified Masson’s Trichrome (MT) stains. The MT was performed 
according to the Trichrome (Masson) Stain kit (HT15-1KT, Sigma-Aldrich) modified in the 
following steps. Firstly, nuclei were pre-stained with Celestine Blue solution (5 min) after 
staining with Gill’s Hematoxylin (5 min). Then, an incubation for 1 hour in aqueous Bouin 
solution was performed to promote uniform staining followed by immersion in a Biebrich 
Scarlet-Fuchsin solution (5 min). To conclude the staining, sections were immersed in a 
Biebrich Scarlet-Fuchsin solution (5 min), followed by a working Phosphotungstic 
/Phosphomolybdic acid solution (5 min), which acts as a mordant, and finally in Aniline Blue 
solution (5 min). Between the immersion in all solutions, samples were rinsed in deionized 
water with the exception of Gill’s Hematoxylin where sections were washed in tap water 
(2min). Sections were diafanized in xylene and mounted in DPX Mountant for histology 
(06522, Sigma-Aldrich®) after a previous incubation at 37ºC to dry. Whole-heart images were 
acquired in an Olympus SZX10 stereomicroscope. High-magnification images were acquired in 
an Olympus CX31 optical microscope and an Olympus DP25-4 camera. 
 The cross-sectional area of CMs was quantified using AxionVision software (V 4.9 1.0, 
Zeiss) based on MT staining. Only CMs that were aligned transversely were considered for the 
quantification of the CM surface area and in each section 30 CMs were randomly chosen per 
area (apex and remote). 
4.5 - Immunohistochemistry 
 Paraffin-sections, obtained as previously described, were dewaxed and rehydrated by 
three changes in xylene, followed by sequential alcohol gradients and rinsing in deionized 
water. Cryosections did not required these steps. 
 If antigen retrieval was necessary, heat-induced epitope retrieval (HIER) or enzymatic 
epitope retrieval (PrER) were applied. For HIER, sections were incubated for 35 minutes at 
98ºC on a water bath, in 10mM sodium citrate, pH 6.0 or in 10mM Tris 1mM EDTA (Tris-EDTA), 
pH 9.0 and let to cool down for 20 minutes at room temperature. For PrER, sections were 
incubated for 10-30 minutes in proteinase-K (0,2mg/mL in tris-EDTA pH8), acid pepsin (750μL 
1% pepsin stock + 743uL HCl 1M up to 75 mL dH2O) or pronase (1mg/mL in 1x PBS) at 37ºC. 
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 Sections were permeabilized with 0.2% Triton X-100 (for intracytoplasmic motifs) or 
with 1% Triton X-100 (for nuclear stainings). Tissue sections were blocked for 1 hour in 4% FBS 
and 1% bovine serum albumine (BSA). If the primary antibody was produced in mouse, 
M.O.M.TM Immunodetection Kit (Vector Lab) was applied to enable blocking of endogenous Fc 
receptors that could be recognized by the secondary antibody [125]. Incubation with primary 
antibody was performed in a humidified chamber 2 hours at room temperature (RT) or, 
alternatively, overnight at 4ºC. Then, sections were incubated with the secondary antibody 
during 1 hour at RT. In order to amplify the fluorescence intensity of several antibodies, 
streptavidin conjugated fluorophores were used: Streptavidin conjugated with Alexa 555 
(S32355, Invitrogen), at 1:500 dilution, Streptavidin conjugated with Alexa 647 (S21374, Life 
Technologies), at 1:400 dilution or Streptavidin conjugated with Allophycocyanin (APC) 
(SA1005, Life Technologies), at 1:100 dilution during 20 min. 
 Sections were mounted with FluoroshieldTM with DAPI (F6182, Sigma-Aldrich) and 
were observed either in a Zeiss Axiovert 200M, an inverted fluorescence microscope, in a 
Leica SP2 AOBS SE or Leica TCS SP5II laser scanning confocal microscope (Leica Microsystems) 
or in GE IN Cell Analyzer 2000, an High-Content Screening microscope. 
 
 
Table 1. List of primary antibodies used and working conditions.  
Antibody Dilution Reference Antigen Retrieval* 
Sarcomeric-α-Actinin (Mouse IgG) 1:400 A7811, Sigma - 
Vimentin (Mouse IgG1/K) 1:50 MS-129-P, Thermo - 
CD31 (Goat IgG) 1:250 sc-1506, Santa Cruz 
Biotechnology 
Tris-EDTA, pH 9.0 
CD45 (Goat IgG) 1:100 AF114, R&D - 
Alpha-Smooth Muscle Actin 
(Mouse IgG) 
1:400 A5228, Sigma - 
phosphorylated-histone3 (Rabbit 
IgG) 
1:800 #3377, Cell Signaling - 
Fibronectin (Rabbit IgG) 1:400 F-3648, Sigma - 
Laminin (Rabbit IgG) 1:400 L9393, Sigma-Aldrich - 
Tenascin-C (Rat IgG) 1:100 LAT-2, Sonnbg - 
Collagen I (Mouse IgG) 1:100 C2456, Sigma Pronase (1mg/mL in 1x PBS) at 
37ºC for 30’ 
Β-1 Integrin (Rat IgG) 1:50 14-0292, eBiosciences - 
Conexin-43 (Goat IgG) 1:400 AB0015-200, SicGen Sodium citrate, pH 6.0 
*Conditions performed in paraffin sections 
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Table 2. List of secondary antibodies used and working dilutions. 
Antibody Dilution Reference 
Alexa Fluor 488 Donkey anti Mouse IgG 1:1000 A-21202, Invitrogen 
Alexa Fluor 594 Donkey anti Mouse IgG 1:1000 A-21203, Invitrogen 
Alexa Fluor 488 Goat anti Mouse IgG 1:1000 A11017, Molecular Probes 
Alexa Fluor 488 Donkey anti Rabbit IgG 1:1000 A-11055, Invitrogen 
Alexa Fluor 568 Donkey anti Rabbit IgG 1:1000 A-10042, Invitrogen 
Alexa Fluor 633 Goat anti Rabbit IgG 1:1000 A21070, Molecular Probes 
Biotinylated Donkey anti Rabbit IgG 1:250 A16033, Life Technologies 
Alexa Fluor 568 Donkey anti Goat IgG 1:1000 A-11057, Invitrogen 
Biotinylated Donkey anti Goat IgG 1:250 A16009, Life Technologies 
Alexa Fluor 488 Donkey anti Rat IgG 1:1000 A-21208, Invitrogen 
Alexa Fluor 568 Goat anti Rat IgG 1:1000 A11077, Molecular Probes 
MOM Biotinylated anti mouse Ig 1:250 MKB-2225, Vector Laboratories 
Biotinylated Goat anti Rat IgG 1:200 BA-9400, Vector Laboratories 
4.6 - High Content Screening: Cardiomyocytic Proliferation 
and Neovascularization Assessment 
 After the acquisition using GE IN Cell Analyzer 2000, the proliferative response of 
neonatal murine hearts at 7d injury and (neo)vascularization at 60d injury were evaluated 
using IN Cell Developer Software (v1.9.2). This software segments each acquisition channel 
and create artificial masks for each structure of interest. CMs were classified proliferative 
when the software detected an overlap between DAPI and s-α-Actinin masks and an intensity 
in pH-3 channel above a predefined threshold. Similarly, the total number of endothelial cells 
was accessed by co localization of DAPI and CD31 expression. The results were normalized 
per area which was quantified in advance by the assembly of individual pictures in ImageJ 
software v2.0.0. 
4.7 - Flow Cytometry and Cell Sorting 
 Flow cytometry was performed to ascertain cardiac fibroblast activation at 7d post-
surgery. Herein, this population was selected based on the expression of CD90 and lack of 
expression of CD31, CD45 and TER119. Cardiac cells were isolated by digestion of cardiac 
tissue fragments with crude collagenase (C2139, Sigma-Aldrich®) at 200μg/ml concentration 
and DNase (A3778, VWR) at 60U/ml in hanks balanced salt solution (HBSS) (H9269, Sigma-
Aldrich®). Collagenase digestions were performed during 15 min at 37ºC until no tissue was 
observed by visual inspection. After each digestion, the suspension was decanted, the media 
collected (cellular portion) and a new collagenase/DNase solution was added to the 
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remaining tissue fragments. The collected cell suspension was mixed with HBSS with 10% FBS 
to neutralize enzymatic activity and was kept on ice. The collected cellular fraction of each 
digestion were combined and washed in FACS medium (0.01% Na-azide 1% FBS in PBS). Cells 
were evenly distributed for each staining in a 96-multiwell plate. After a first wash in FACS 
media, cells were incubated during 30 min with the antibody cocktail (table 3) on ice and in 
the dark. Cells were washed twice in FACS media and transferred to FACS tubes. In order to 
exclude nonviable cells from the analysis, 0.5% of propidium iodide (P4170, Sigma-Aldrich) 
was added to the cell suspension 1-2 min prior to analysis. Fifty thousand events (of 
appropriate size and complexity) per staining were acquired in the cytometer FACS Canto II 
(BD Biosciences). Subsequent analysis and graphing were executed in FlowJo VX software. 
 For cell sorting, the same procedure was used with exception to the fact that cells 
were resuspended in Sorting Buffer (1mM EDTA, 25mM HEPES, 2% FBS in PBS) before being 
transferred to FACS tubes. Four cell populations were sorted using FACS ARIA II (BD 
Biosciences), according to CD90, PDGFRa (CD140a), Sca1 and CD44 expression. Thus, the cell 
signature of each population chosen was: 1) Lin-CD90+CD140a+CD44+Sca1-; 2) Lin-
CD90+CD140a+CD44-Sca1-; 3) Lin-CD90-CD140a+CD44+Sca1+/- / Lin-CD90+CD140a-CD44+Sca1+/- / 
Lin-CD90-CD140a-CD44+Sca1+/- and 4) Lin-CD90+CD140a+CD44+Sca1+. 
 
 
Table 3. List of conjugated antibodies used in Flow Cytometry and specifications of the 
working dilution. 
Antibody Dilution Reference 
CD31-PeCy7 (Rat IgG2a) 1:100 25-0311, eBiosciences 
CD45-PeCy7 (Rat IgG2b) 1:100 25-0451, eBiosciences 
TER119-PE (Rat IgG2b) 1:100 116208, Biolegend 
CD90.2-FITC (Rat IgG2b) 1:100 553013, BD Pharmingen 
CD140a-APC (FL4) (Rat IgG2a) 1:100 135907, Biolegend 
CD44-APC/Cy7 (Rat IgG2b) 1:100 103027, Biolegend 
Sca-1-PE 1:100 108107, Biolegend 
4.8 - Neonatal Heart Digestion 
 Neonatal hearts (7 days post-injury/sham) were harvested and subdivided in apex, 
ventricles and atria. Then, each sample was cut into small fragments (approximately 2mm), 
before being flash frozen in liquid nitrogen, until further use. Then, fragments were thawed 
at RT and fixed with 4% paraformaldehyde (PFA) for 2 hours with stirring (100 rpm). Following 
fixation, fragments were digested with collagenase type II (Worthington, CLS-2) (3 mg/ml in 
HBSS) overnight at 37ºC (100 rpm) and mechanically dissociated until no fragments were 
detected. Additional digestions could be required depending on fragment original size and for 
that the collagenase solution was changed in 24h periods. In order to inactivate collagenase, 
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equal volume of HBSS with 10% FBS was added and kept at 4ºC until the digestion was 
complete. At this stage, cells can be stored at 4ºC in FACS media (containing 0.01% of Na-
Azide) to prevent contaminations. These samples were used for cytospin immunofluorescence 
or for imaging flow cytometry. 
4.9 - Imaging Flow Cytometry 
 Cell suspensions were centrifuged at 300G for 10min and the cellular portion was 
then resuspended in FACS media (0.01% Na-azide 1% FBS in PBS) and permeabilized by 1X BD 
Perm/Wash™ Buffer during 15 minutes at RT. Incubation with primary (anti sarcomeric-α-
Actinin (1:400, A7811, Sigma)) and secondary antibodies (Alexa Fluor 488 Donkey anti 
Mouse IgG (1:1000, A-21202, Invitrogen) lasted for 2 hours and 30 minutes on ice, 
respectively. Both antibodies were diluted in 1X BD Perm/Wash™ Buffer and incubations were 
separated by two washes with 1X BD Perm/Wash™ Buffer at 2000 rpm (240G). Finally, they 
were ressuspended in 1X PBS and kept at 4ºC until acquisition. Immediately before acquiring, 
cells were filtered (100µm cell strainer) and their nuclei was stained with 200 µM of DRAQ5 (5 
mM, Biostatus). 
 CM morphometric analysis was performed using IDEAS® software. This software 
calculates several features of CMs (area, major axis, minor axis and aspect ratio) and allows 
mask creation (definition of a specific area) to access nuclei number. Thus, unfocused cells 
were promptly removed by eliminating cells with Gradient RMS smaller than 40 and debris 
and duplets were excluded by removing the objects with small area and high aspect ratio. To 
ensure that the analysis was focused on CMs, remaining events were plotted by the intensity 
of s-α-Actinin and DRAQ5 and double positives selected for subsequent analysis. Whenever 
the aspect ratio was smaller than 0.55, cardiomyocytes were classified as “Rod”. 
4.10 - Immunocytochemistry 
 Cytospin immunofluorescence was performed following heart digestion. Isolated 
cardiac cells were plated onto glass slides using cytospin (Shandon Cytospin® 4, Thermo 
Scientific) and spun for 5 min at 130G. Cells were permeabilized with 0.5% Triton for 7 min 
and washed three times in PBS with 0.2% Tween. Then, cells were incubation for 2 hour with 
the following primary antibodies diluted in 1X PBS with 0.2% Tween: anti sarcomeric-α-actinin 
(1:400, A7811, Sigma) and anti-phosphorylated-histone3 (pH3) (1:800,#3377, Cell Signaling). 
These antibodies were used to stain CMs and karyokinesis, respectively. After three washes 
with 1X PBS with 0.2% Tween, 3 min each, samples were stained with the secondary 
antibodies for 30 min at RT, in the dark. Finally, nuclei were stained with DAPI for 10 minutes 
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and slides mounted in a PBS glycerol solution (1:9) with 2.5% n-propyl-gallate (Sigma-Aldrich) 
without DAPI. 
4.11 - Statistical Analysis 
 Data statistical analysis was performed with IBM SPSS Statistics 22 software. Shapiro-
Wilk’s test was used to evaluate if the data displayed a normal distribution. Samples 
considered as outliers were excluded from the statistical analysis at this point. Then, 
homogeneity of the sample was tested by Levene’s test. These results defined the statistical 
test(s) used further. Normally distributed and homogeneous data were tested with parametric 
tests (independent samples T Test for 2 groups or one-way ANOVA for 3 or more groups). 
Tukey’s post hoc test for correction of multiple comparisons was performed whenever 
significant differences were found between 3 or more groups. 
 Non-normal distributed and/or heterocedastic data were tested with non-parametric 
tests (Mann-Whitney U Test for two groups or Kruskal-Wallis one-way analysis of variance for 
3 or more groups). Again, multiple comparisons were executed when 3 or more groups were 
considered statistically different by Kruskal-Wallis one-way test. The statistical significance 
level chosen for all statistical tests was p-value (p)<0.05. Results were shown as mean ± SD of 
the mean and are marked with one asterisk (*) if p<0.05, two (**) if p<0.01 and three (***) if 
p<0.001. 
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Chapter 5  
Results 
5.1 -  Neonatal Hearts Do Not Fully Recover After Apex 
Resection 
The robustness of the neonatal model of apex resection has been questioned since 
several technical variables have been reported to affect the injury outcome, namely the 
resection severity, the type of injury and even minor differences on the surgical procedure, 
which subsequently impact on the amount of scar formation [38, 41].  
We established the exact same surgery protocol as described previously by Porrello et 
al. for apex resection in P1.5 C57Bl/6 neonatal mice, using the exposure of the LV lumen as a 
standardizing method for the resection size. The size of the lesion was determined 
immediately after resection, by the length of the heart vertical axis, normalized by the 
animal-body weight. The heart height/body weight showed a significant reduction of 13,8% 
when compared to sham-operated animals (p-value=0.011) (Figure 9). The low deviation of 
the resection size between injured animals showed reproducibility of the procedure. 
Furthermore, the extension of apex removal at our laboratory is comparable with other 
reports [32, 40, 41], legitimating further comparisons. The follow-up of the animals at 60dpr 
showed a statistical significant tendency for a persistent decrease on heart height/body 
weight of 13,08% (p-value=0.019) (Figure 9), which is indicative that apex-resected hearts do 
not undergo significant reestablishment of the resected region.  
Aiming at detailed examination of histological alterations at the injury site, hearts 
were harvested and representatively sectioned and stained with Masson’s Trichrome (Figure 
10 (A)). The extent of the injury was estimated by determining the percentage of sections 
exhibiting cardiac fibrosis and/or elicit signs of tissue damage. Throughout the study we 
found a statistically significant reduction on the injury size of 28,1%, 42% and 58,3% between 
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0 and 21dpr (p-value=0.020), 21dpr and 60 dpr (p-value=0.018) and 0 and 60 dpr (p-
value<0.001), respectively (Figure 10 (C)). Interestingly, although the heart is growing, the 
fibrotic scar maintains the same width throughout the injury response (Figure 10 (D)). 
 
Figure 9. Assessment of the lesion size and heart recovery after surgery. The ratio heart height/BW 
was accessed at 0 and 60 days post-surgery (left), revealing surgical reproducibility and reduction of the 
cardiac long axis by 13% throughout the study. On the left panel, representative stereomicroscope 
images are shown for sham-operated and apex-resected hearts at the days of the surgery and 60 days 
after the procedure. Values are presented as means ± SD. Scale bar: 1mm. 0dps (n=11); 0dpr (n=11); 
60dps (n=4); 60dpr (n=6). 
 
 Histological analysis of the injury site showed extensive deposition of cardiac fibrosis 
in the central sections of the heart, were the lumen was exposed after resection, whereas 
the surrounding apex region displays myocardial integrity. Of note, sham-operated hearts did 
not show any relevant histological and anatomical alterations (not shown), apart from 
epicardial surgical adherences, which is a common phenomenon to both experimental groups 
and relates to the surgical intervention. Importantly, at 60 days post surgery, all hearts 
analyzed displayed a transmural scar. This data contrasts with the results obtained at 21 dpr, 
a period in which a small amount of scattered myocardial fibrosis was present at the apex 
region (Chapter 2, Figure 6). Overall, these results are indicative that the apical tip, where 
extensive remodelling (collagen-rich scar) was found, does not regenerate efficiently (Figure 
10 (B)). However, these results do not invalidate the hypothesis that the apex region 
adjacent to LV free wall and to the intraventricular septum may have undergone 
regeneration, as fibrosis was restricted to the epicardium and not found within the 
myocardium of these areas (Figure 10 (B), left). 
 (Neo)vascularization, a requirement for regeneration, was accessed by semi-
automatic quantification of CD31 (endothelial-associated marker) expressing cells (CD31+) 60 
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days following surgery. We found that vascularization was not impaired, being slightly but 
significantly increased in comparison to sham operated animals. Restricting the analysis to 
the apex region, revealed that the number of CD31+ cells per area was increased in 
central/fibrotic sections when compared with peripheral/non-fibrotic ones in both injured 
(33%, p-value=0,005) and sham operated animals (18%, p-value=0,04). Consistently, apex 
resected hearts showed a statistical significant increase in the percentage of CD31+ cells in 
central (14,9%, p-value=0,09) and in peripheral sections (30,8%, p-value=0,014) when 
compared to surgical controls (Figure 10 (E)). Interestingly, in the remote area (above 
papillary muscles) of central sections the trend for an increased neovascularization persists 
after apex-resection (Figure 10 (F)), although statistical significance was not obtained. 
 
5.2 - Cardiomyocyte Proliferation Is Activated Upon 
Neonatal Apex Resection 
 One fundamental feature of the neonatal mouse resection model noted by Porrello et 
al. is an increase of CM cell-cycle reentry upon injury. In contrast, Andersen et al. did not 
observe the same mechanism in resected hearts. To test whether resection results in an 
augment in cell cycle activity, cardiomyocytic proliferation was automatically quantified on 
cryosections using an algorithm that co-localizes α-actinin, DAPI and pH3 staining, which 
label CMs, nuclei and karyokinesis, respectively (Figure 11 (A)). When evaluating the 
myocardium below the papillary muscle, CM proliferation occurs at a significant higher rate in 
the apex resected group when compared to the sham group (p-value=0.001), representing a 
fold-increase of 2.44 (Figure 11 (C)). 
 To reinforce this idea, a similar analysis was performed on cytospins of isolated CMs 
(Figure 11 (B)). Accordingly with the previous analysis, proliferative CMs were identified 
through the co-localization of of s-α-Actinin, DAPI and pH3 staining in the same cell. In this 
case, injured hearts have a greater fold-increase (3.45) in proliferating CMs, yet this result 
did not reach statistical significance (p-value=0.149) (Figure 11 (D)). This analysis will be 
repeated to increase the biological replicates and strength statistical robustness. 
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Figure 10. Characterization of the neonatal cardiac injury response. (A) Masson’s Trichrome 
representative sections of apex-resected hearts at 60 days post-apex resection. Scale-bars: 2 mm (B) 
High power images of Masson’s Trichrome focusing the injury site with arrows highlighting collagen 
deposition. Scale bar: 100 μm. (C) Percentage of heart sections displaying signs of lesion throughout the 
study (0, 21 and 60 days post-apex resection). Although the heart is not fully recovered after 60 days 
post-apex resection, the injury representativeness decreases, however, scar width is maintained 
through time (D). Values are presented as means ± SD. 0dpr (n=8); 21dpr (n=4); 60dpr (n=6). (F-G) 
Neovascularization at 60 days following injury. The number of CD31+ cells per area was accessed in the 
apex (E) and remote zone (F), demonstrating that in apex-resected hearts, vascularization was not 
impaired. Values are presented as means ± SD. 60dps (central n=12; peripheral n=6); 60dpr (central 
n=14; peripheral n=11). 
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Figure 11. Proliferative behavior of CMs at the injury site. (A-B) Representative proliferative CMs of 
the apex region at 7days after surgery, in situ (A) and following CM isolation (B). Scale bar: 10μm. (C-D) 
CMs proliferation is significantly increased on the apex of injured animals when compared to sham-
operated controls at 7 days post-surgery. (C) cryosections (7dps n=8; 7dpr n=7); (D) cytospin (7dps n=7; 
7dpr n=7). Values are presented as means ± SD.  
 
  
 The loss of CM proliferative potential is commonly attributed to the development of a 
terminally differentiated phenotype that is characterized by the presence of the 
differentiated sarcomeric cytoskeleton and binucleation [73]. In order to assess whether after 
resection the rate of CMs displaying an immature phenotypes was increased, morphometric 
analysis of the CMs was performed (Figure 13). Hence, when the aspect ratio is bigger than 
0.55, CMs were classified as “round”, correlating with a more immature phenotype, 
otherwise CMs were classified as rod (mature phenotype). At 7 days post injury, imaging flow-
cytometry analysis revealed that round CM were increased by 26,9% and 111% in the apex and 
remote areas, respectively, of the apex-resected group (p-value = 0.030 and 0.012, 
respectively). Interestingly, this morphometry correlates with a more immature CM 
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phenotype, which is thought to be more proliferative [126]. Nonetheless, rod-shaped CMs 
were always the predominant population among the total population of CMs (Figure 12 (A)). 
Intriguingly, the global area of CM was statistically higher in the apex of injured animals 
(Figure 12 (B)). In accordance, the area of mature CMs (rod-shaped) in apex-resected hearts 
is increased by 21,6% (p-value 0,021), which could explain the increase in global CM area. In 
the remote zone an opposite trend was observed since rod-shaped CM were 13,9% smaller (p-
value=0.037) (Figure 12 (C)). These results are indicative of a local compensatory CM 
hypertrophy in the border zone of the injury, whereas at remote regions CMs are smaller. 
  
 
 
Figure 12.  CM morphometric parameters at 7 days following surgery. By imaging flow cytometry, CM 
morphology was accessed showing an increase on the number of immature CMs (A). The global CM area 
was increased in the apex (B) and these are associated to a bigger area of rod-shaped CMs (C). Values 
are presented as means ± SD .7dps (n=7); 7dpr (n=7).  
 To assess whether this hypertrophic phenotype was maintained throughout the study, 
the surface area of cross-sectioned CM was assayed at 60 days after apex resection. In fact, 
no signs of hypertrophy were detected and CM cross-section area was considerably smaller in 
injured hearts both in apex and remote zone when compared to sham, although statistical 
significance was only reached in the remote area (Figure 13 (A)). Further analysis revealed 
that CM surface area in the apex diminishes especially in areas adjacent to the injury (p-
value=0.044) whereas, in lateral/peripheral sections, the same tendency is verified although 
no statistical significance is achieved (Figure 13 (B)). 
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Figure 13. CM surface area quantification. CM surface area of injured mice, manually quantified in 
histological sections, showed a decrease when compared to sham operated animals in apex and remote 
areas (A). 60dps (n=28); 60dpr (n=64). Within the apex (B), a notorious difference was observed in CM of 
central/fibrotic sections between groups. 60dps (central n=14; peripheral n=14); 60dpr (central n=32; 
peripheral n=26). Values are presented as means ± SD.  
  
Considering that a decrease on CM size may impact on efficient intercellular communication, 
we evaluated the expression of Cx43, the main cardiac gap junction protein, on the apex 
area of apex-resected and sham-operated animals. An evident subexpression of this protein in 
injured hearts was observed, mainly in apex regions where collagen deposition in the 
intercellular space was more perceptive (Figure 14). 
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Figure 14. Representative images of Cx43 expression-pattern 60 days after surgery. The apex of 
resected hearts clear down regulation of this gap junction protein. Scale bar: 1 mm. 60dps (n=3); 60dpr 
(n=6). 
5.3 - Dynamic Deposition of Extracellular Matrix Instructs 
the Myocardium Upon Injury 
 Several evidences support that the production of ECM is one of the mechanisms 
activated during cardiac regeneration in lower vertebrates [127]. To address in detail the 
extracellular and cellular dynamics aforementioned in the Preliminary Data section (Chapter 
2), we focused primarily on the deposition of Fn and Tn-C, which we have shown to be 
upregulated following apex-resection (Figure 7). 
 The deposition of ECM was assayed at 48h and 7 dpr, i.e. in the peak of inflammation 
and fibroblast proliferation, respectively (Figure 15). At an early stage (48 hours post-apex 
resection), the deposition of Fn and Tn-C is associated with hematopoietic cells (CD45 
expressing cells) as, by immunofluorescence confocal microscopy, we are able to detected a 
co-localization of these three markers (Figure 16). In contrast, at later stages (7 dpr), Fn and 
Tn-C become co-localized with myofibroblasts (α-SMA+ expressing cells), indicating a shift in 
the cell types responsible for the production and deposition of these two ECM components 
(Figure 15). Considering the pattern of Fn and Tn-C deposition, although largely overlapping, 
Fn has a broad expression pattern throughout the injury site than Tn-C, which is confined to 
the boundaries between injured and healthy tissue (Figure 16). 
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Figure 15. Cellular source of Fn and Tn-C at the injury site. Representative immunofluorescence 
images at injury site, 48h and 7 days following apex resection, demonstrating a shift in the cellular 
source of both proteins. Scale bar: 30 μm. 48hpr (n=4); 7dpr (n=4). 
 
Figure 16. Fibronectin and Tenascin-C have distinct deposition patterns. Representative images of 
Tn-C and Fn deposition in the apex, 7 days post-apex resection. Co-localization of these proteins is 
observed, however Fn presents a more disperse expression pattern when compared to Tn-C, which is 
restricted to the margin of the injury. Scale bar: 30μm. (n=4) 
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 We then hypothesized that ECM deposition would play an instructive role at injury 
site by promoting higher levels of cardiomyocytic proliferation and/or CM migration to the 
injury site. Once the proliferation of CMs is up-regulated at 7 days post-apex resection 
(Figure 11) we focused on this time-point. Mitotic CMs were predominantly found in the 
vicinity of these two extracellular matrix components and, importantly, CMs exhibit the 
expression of CD29 (also known as integrin-β1), an important integrin chain that mediates 
cell-matrix interactions [104] (Figure 17). 
 
 
 
Figure 17. The instrutive role of ECM. Representative images of mitotic cardiomyocytes (s-α-
Actinin+pH3+) in the vicinity of extracellular matrix deposition (Fn and Tn-C) at 7 dpr. Analysis of 
adjacent sections showed that proliferative CMs express CD29 and are associated with Fn-rich regions.  
Scale bar: 30 μm. (n=4) 
5.4 - The Role of Cardiac Fibroblasts following Neonatal 
Cardiac Injury  
 Considering that, after the peak of inflammation, Tn-C and Fn are mainly produced 
by myofibroblasts (Figure 17) and that collagen is being deposited the core of the lesion 
(Figure 10 (B)) at later time-points after apex-resection; we postulated that fibroblasts are 
activated during this process. To unveil their intervention in response to injury, flow 
cytometric profiling of these cells was performed. The fibroblast population was herein 
defined by the expression of CD90 (Thy-1), a well-reported marker of cardiac fibroblasts 
[117], after exclusion of endothelial (CD31), hematopoietic (CD45) and erythroid cells 
(TER119). 
 Among the markers ascribed in the previous ontogenic characterization (Figure 8 
Chapter 2), we decided to ascertain CD44, Sca1, CD105 (Endoglin), CD106 and CD140a 
(PDGFRα) expression levels upon apex resection. CD105 is an accessory glycoprotein of TGFβ 
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receptor complex that modulates the cell response to several TGFβ superfamily ligands, 
namely TGF-β1. This signalling pathway promotes type I collagen synthesis and fibrosis [128]. 
CD106 (also known as vascular cell adhesion molecule 1-VCAM1) is involved in angiogenesis, 
cardioprotection and also in the initiation of the inflammatory process [20, 129]. 
 At 7 post-surgery, the percentage of CD90+and CD90+CD106+ cells was not different 
between injured and sham-operated mice. In contrast, a significant increase was observed in 
the frequency of CD90+CD44+ and CD90+Sca1+ (p-value=0.27, and 0.13, respectively) whereas 
CD90+CD105+ population significantly decreases (p-value=0.016). Additionally, considering the 
proliferation in the stromal compartment (CD31-CD45-, TER119-), no statistically significant 
differences were found on Ki67 expression levels between injury and sham-operated animals. 
However, the percentage of Sca1+ proliferating cells (p-value<0,001) almost doubled in injury 
conditions (Figure 18). 
  
 
Figure 18. Phenotypic characterization of cardiac fibroblasts 7 days after apex-resection. CD90 
expression profile (left) and proliferation (Ki67, right) of the stromal compartment (CD31-CD45-TER119-) 
was investigated post-apex resection and post-sham surgery (left). 7dps (n=6); 7dpr (n=5).  
  
 Given the extensive overlap between these markers, we decided plot the same data 
resorting to Venn Diagrams, which allows comparison of three markers simultaneously. Thus 
and looking inside the cardiac fibroblast compartment (CD90+ cells), we display the co-
expression of CD140a, CD44 and Sca1 (Figure 19). In this representation, the main population 
differences between sham and injured hearts reside on the increase of CD90+CD44+ (red), 
CD90+CD44+CD140a+ (purple) and CD90+Sca1+CD44-CD140a- (yellow), and decrease on 
CD90+Sca1-CD44-CD140a+ (blue) cardiac fibroblasts. However, only CD90+Sca1+CD44-CD140a- 
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population reached statistical significance (p-value=0.036) whereas CD90+Sca1-CD44-CD140a+ 
obtained a p-value of 0.059. 
 Based on this information, we strategically sorted 4 populations with the most 
distinct expression profiles (see Material and Methods Cell Sorting). qPCR of these populations 
will be valuable to detect differences at the transcriptomic level which could translate in 
different roles on the cardiac injury response. This experiment will be performed in the near 
future, and therefore this results will be out of the scope of the herein dissertation. 
 
 
Figure 19. Venn Diagrams of the stromal heart populations 7 days following injury. The major 
differences noticed were in CD90+CD140a+ (blue), CD90+CD44+CD140a+ (purple) and CD90+Sca1+ 
(yellow) populations. 7dps (n=6); 7dpr (n=5). 
       
 
  
39 
 
Chapter 6 
Discussion 
 Cardiovascular diseases are the leading cause of death worldwide, representing 30% 
of global mortality. Unfortunately, available projections show that this tendency will persist 
and, currently, the only long-term effective therapy for heart failure is cardiac 
transplantation [1]. Hence, the development of novel therapies to re-establish the 
myocardium or, at least, to improve cardiac repair following injury are mandatory. 
 Looking into heart evolution along phylogeny, several evidences suggest the existence 
of a compromise between adaptation and regenerative capacity [2]. Albeit mammalian heart 
has been considered genuinely unable to regenerate upon injury, a ground-breaking discovery 
reported that murine hearts retain an intrinsic yet transient regenerative capacity. Hearts 
from 1-day-old mouse were reported to fully regenerate from apex resection within 21 days. 
In contrast, 7-day-old mice lack regenerative capacity and hearts develop a reparative 
response, originating a collagen-rich scar, and therefore, compromising cardiac function [3]. 
This exciting data brought a valuable platform to dissect molecular networks governing 
cardiac regeneration and thus propelling the design of new cardiac therapies. Regardless of 
apex-resection injury model has been replicated in other laboratories, cited over 300 times 
and corroborated by distinct injury models [4-9], in 2014, Andersen et al. refuted the 
existence of neonatal cardiac regeneration, reporting a massive collagen deposition even 
when the lesion was inflicted in the first week of life [10]. A consensus on the field is still 
missing although independent studies have already committed in determining the basis for 
such different outcomes. In this sense, herein work aims to understand which reparative or 
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regenerative features prevail after apex resection, focusing particularly on the dual role of 
cardiac fibroblasts and ECM deposition. 
 Neonatal apex resection model was successfully established in our lab however 
technical differences, in comparison to previous studies, should be considered. In the herein 
work, surgery was performed in P1.5 C57BL/6 neonates, i.e. 36h post-birth. Porrello et al., 
analysed P1 ICR-CD-1 heart as such, and assuming that they performed the surgery in the first 
24h post birth, our injury is set half a day later, which is still within the reported 
regenerative time window. Moreover, distinct strains might have different responses to injury 
and C57BL/6 mice have been considered non-healers [11], however, Andersen et al. did not 
found any strain-specific responses between this strain and the ICR-CD-1. 
 In resemblance to Porrello et al., we used the exposure of the left ventricle lumen, 
as a standardizing method for the resection size. This approach resulted on a reproducible 
outcome as a 14% reduction is consistently obtained in heart height/body weight ratio (Figure 
9). Even still, the severity has been assayed by different methodologies (ventricle weight, 
surface area and heart weight/body weight) across laboratories, jeopardizing direct 
comparison of data. In our hands, the injury extension is within the range mentioned in the 
available reports. In spite of our best efforts, we failed to weight accurately the LV of the 
animals, as the resected tissue weight is within the deviation of our precision weighing scale 
(0.01 mg). Indeed, C57BL/6 mice are smaller than the ICR-CD-1, and therefore, to attain a 
similar resection size, the weight of the resected tissue is smaller, limiting quantification. 
Additionally, the survival rate of apex-resected animals to the surgery (≈85%, Figure 4) is 
similar to other reports, supporting the successful establishment of the injury-model. 
Notwithstanding, at 60 days after surgery the heart height/body weight ratio variation 
between groups suggests that the injured heart did not recover the apex. Although the scar 
width is maintained throughout time, its representativeness in the heart diminished. This 
could be justified by the growth of the heart; however, we cannot disregard the possibility of 
partial tissue reestablishment through activation of regenerative mechanisms. At the 
histological level reparative mechanisms are evident at 60 dpr since a full-thickness scar is 
formed in the centre of the apex, resembling a small aneurysm (Figure 10 (B)). Interestingly, 
although interstitial collagen deposition is evident in apex-resected hearts at 21dpr, none of 
the analysed hearts displayed a full-thickness scar. This evidence is indicative that from 21 to 
60 dpr, myocardial fibrosis expanded to form an aneurism-like structure, whereas in the 
adjacent regions, where disperse collagen was identified, the myocardium was mainly 
restored. This scenario is consistent with the activation of CM proliferation in the border-
zone of the injury, i.e. in the LV and interventricular septum (IVS) myocardium, which may 
provide gradual replacement of peripheral scar tissue by newly contractile myocardium. 
Clearly, the augmented CM proliferation (Figure 11) is not sufficient to fully recover the 
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myocardial wall in the centre of the apex. Hence, these results contrast to the original 
description of neonatal apex regeneration, in which fibrosis was reported as non-evident [3]. 
The reestablishment of the new vasculature is also a pivotal mechanism for heart 
regeneration as otherwise, blood supply to the damaged area is ineffective/absent [12]. 
Interestingly, no impairment on the neovascularisation was observe throughout the heart, and 
therefore the regenerative mechanisms underlying vessel formation are efficiently activated 
following apex-resection rendering this injury-model as a good system to study cardiac neo-
angiogenesis. Moreover, the reestablishment of the vasculature levels occurs even in the 
fibrotic zone contrasting to the injury response upon AMI in the adult heart [13]. The innate 
capacity for angiogenesis reactivation in neonatal hearts may rely on the immune system 
once it was demonstrated that monocytes/macrophages influence neovascularization during 
cardiac regeneration. Interestingly, following monocytes/macrophage ablation, cardiac 
regenerative capacity is impaired mainly by an insufficient neovascularization [14]. Our 
results concerning revascularization of the resected area clearly contrast to the Andersen et 
al. report, which demonstrated that the damaged apex comprises modest vascularisation [10] 
 The CM cell cycle re-entry was the first postulated mechanism for the restoration of 
myocardial tissue after apex resection [3]. Nevertheless, within the controversy settled 
around neonatal cardiac model, CM proliferation was refuted by Andersen et al. [10]. High-
content imaging analysis showed that at 7 days post-surgery, CM proliferation was 
significantly increased in the apex region, when compared to sham operated controls. 
Reinforcing this premise, a different analysis procedure (manual quantification on cytospin) 
revealed the same tendency. Although, no CM lineage tracing has been performed in the 
herein MSc Thesis, the hypothesis that best suits our data is that newly formed CMs drive 
from pre-existing ones, once we successfully show an increase in mitotic CMs with sarcomere 
disassembly (Figure 11), characteristic of dedifferentiation events [15]. Nevertheless, we 
cannot exclude the possibility that stem or progenitor cells also contribute to this process. 
 Interestingly although both regenerative and reparative mechanisms have been 
activated and hearts are not fully restored at 60 dpr, we did not found any evidence of 
compensatory hypertrophic growth. On the contrary, injured hearts displayed smaller CMs 
when compared to sham operated animals. Nevertheless, at 7 dpr, rod-shaped CMs display 
increased areas when compared to the respective sham-operated control. We hypothesized 
that this is a transient, yet necessary response to promote wound closure once hypertrophic 
CMs are only detected in the apex region. Curiously, the area variation levels between 7 and 
60 dpr are approximately equal to the previously found at 7dpr (≈15%), which indicates a 
recovery of the CM morphometric parameters at latter time-points.  
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 AMI causes an increase in myocardial resistivity and a decrease in conduction velocity 
that culminate in an arrhythmic behavior [16]. Cardiomyocytic gap junctions are determinant 
in this process and in prolonged hypoxia environments, downregulation and internalization of 
Cx43 at gap junctions occurs [17]. Our results showed a downregulation of Cx43 on injured 
hearts, and although the electrical activity of the hearts at 60 days post-surgery was not 
evaluated, this information suggests impairment in the conduction system. Moreover, 
subexpression of Cx43 occurs in areas where the deposition of collagen is notorious. 
Interestingly, a study demonstrated that a reduced expression of Cx43 promote fibrosis during 
pathophysiological condition [18]. 
 To dissect the biological players involved in the injury response, the ECM dynamics 
was characterized. In our preliminary data we showed that the neonatal injury response at 
P1.5 involves, in an initial stage, the formation of a blood clot and consequent recruitment of 
inflammatory cells. Between 5 and 7 days post-surgery, the inflammation enters in its 
resolution phase, which is concomitant with the appearance of fibroblasts and 
myofibroblasts. Finally, 21 days following injury, the myocardium partially recovers its 
expression pattern, suggesting heart recovery at some extent (Figure 5). Interestingly, during 
this process, ECM is reshaped, which is highlighted by Fn and Tn-C expression. These ECM 
proteins are significantly upregulated from 48hpr until 21dpr. Curiously, there seems to be a 
double origin for their deposition, as primarily it is associated with hematopoietic cells and 
latter with myofibroblasts. Although Fn and Tn-C are derived from the same cellular sources, 
their deposition patterns are distinct at 7 dpr. Fn is a known mediator of several cellular 
interactions such as migration, proliferation and angiogenesis, being widely expressed in 
healthy myocardium [19]. On the other hand, Tn-C is a counter-adhesive glycoprotein and is 
able to promote cell proliferation, migration or regulate cell attachment [20]. Contrarily to 
Fn, this protein is barely detected in the normal adult heart but transiently expressed when 
associated with tissue remodeling [21]. In zebrafish, injury-mediated Fn and Tn-C deposition 
is essential to promote CM migration to the injury site [22, 23] whereas in cultured 
mammalian CMs, Fn induces proliferation through β1 integrin (also known as CD29) [24]. In 
newt, alongside with hyaluronic acid, both Fn and Tn-C promote CM cell-cycle reentry [20]. 
Altogether, the accumulation of these molecules in the damaged myocardium likely 
recapitulates, to a limited extent, the regenerative response of lower vertebrates, improving 
cell migration to the injury site. However, in adult human hearts, Tn-C and Fn expression is 
observed during wound healing upon myocardial infarction, originating a transient matrix 
necessary for further organization of other proteins like collagen [25].  
 Since Fn and Tn-C have also been associated with CM proliferation [20], we 
hypothesized their involvement with the increased proliferation of CM after apex-resection. 
To this end we aimed to co-detect these markers with proliferating CMs. However, as our Fn 
and pH3 antibodies were produced in the same species, we were not able to simultaneous 
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detect the expression pattern these two proteins. As an alternative strategy, we used 
consecutive sections (Figure 17) for each immunostaining. Proliferating CMs were not found 
on Tn-C rich areas, which might be explained due to the counter-adhesive properties of this 
protein. Contrarily, higher CM mitotic levels were found in the vicinity of Fn deposition at the 
injured area, and importantly, proliferating CMs express CD29 (integrin β1), which may be 
one of the element mediating cell-matrix interactions.  
 The resolution of cardiac injury encompasses microenvironmental alterations that 
seem to trigger fibroblast activation and proliferation. Although the total amount of CD90+ 
fibroblast was not altered, within the CD90 compartment, we observed a statistical increase 
in the percentage of cells expressing CD44 and Sca1. This data is anticipated since CD44 and 
Sca1 are upregulated in the injured adult heart, being associated to the activation of 
fibroblasts and as a progenitor-like phenotype, respectively [26, 27]. Interestingly, CD105+ 
(aka endoglin) cardiac fibroblasts were downregulated in injured hearts when compared to 
sham operated animals. In adult hearts, reduced CD105 expression attenuates cardiac fibrosis 
and preserves left ventricular function by limiting TGFβ1 signaling and type I collagen 
synthesis by cardiac fibroblasts [28]. The observed reduction on CD105+ cardiac fibroblasts 
may suggest that cardiac fibroblast after apex resection change phenotype towards the 
production of less collagen at 7 dpr, a period in which CM proliferation occurs. Furthermore, 
considering the proliferative rate of these populations, only Sca-1+ cells proliferate 
consistently following injury. On the other hand, the evident increase on CD44+ cardiac 
fibroblasts, is more likely a product of phenotypic alterations resultant from cardiac 
fibroblast activation and differentiation in myofibroblasts. Despite that the obtained 
differences on cardiac fibroblast dynamics are subtle; their frequency is most likely diluted 
since the cytometric analysis was performed with the whole heart rater that with the 
damaged area. We developed a sorting strategy to isolate cells that have a more dissimilar 
phenotype comparing to sham, in order to study their transcriptomic profile. Thus, based on 
their transcriptome we aim to distinguish populations of fibroblasts and correlate their 
expression profile with a more regenerative or reparative profile. 
 Overall, our results suggest that upon apex-resection murine hearts undergo 
neomyogenesis, ECM remodelling, neovascularisation and do not show signs of hypertrophy or 
cardiac dysfunction. Intriguingly, our results do not fully replicate any of the previous 
reports. At 21 days following injury, Porrello et al. reported full restoration of myocardium 
with minimal fibrosis whereas Andersen et al. described the accumulation of a massive scar 
in the resection site and no evident signs of CM proliferation. Indeed, at histological level, 
our results resemble more Andersen et al. although with less robust collagen formation. 
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However, a detailed analysis of the injury response unveils similarities with Porrello et al., 
namely higher CM proliferative rates and no evidences of hypertrophy. Concerning the lack of 
reproducibility among reports, the lack of representativeness on the analysed tissue sections 
has been appointed to be the origin of such discrepancies [29-31]. Thus, a diminished 
representativeness can mask the injury site, misleading the final interpretation. Porrello et 
al. only sliced 140 section of 5μm per heart whereas Andersen et al. obtained 820. To address 
this technical limitation we have performed representative sections of the whole heart with 
constant intervals between each section, thereby increasing robustness of analysis. 
Furthermore, the duration of the previous studies (21d) might have been insufficient to 
address the final outcome of the heart injury response once the expansion of the myocardial 
collagen-rich scar occurs from 21d to 60d. An important limitation of the herein work is the 
lack of functional results at 60d post-surgery, which constitute one of the experiments to 
address in the near future (Table 4).  
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Chapter 7 
Conclusion 
 The herein work discriminates the cellular and extracellular dynamics of the neonatal 
heart injury response, until 60 days following surgery (Figure 20). We demonstrate that 
immediately after injury, a blood clot is formed to prevent extensive hemorrhage, which is 
also the origin of inflammatory cells. Then, ECM remodeling takes place, mainly by the 
overexpression of Fn and Tn-C, which may be important to promote CM proliferation and/or 
migration towards the injury area. Although CMs re-enter in the cell cycle, CM turnover is 
insufficient to ensure restoration of the lost tissue. Thus, fibroblasts and myofibroblasts 
orchestrate the establishment of a fibrotic scar in the center of the lesion, promoting cardiac 
fibrosis, which until 21dpr did not affect systolic function.  
Interestingly, following apex-resection we report both regenerative (neomyogenesis, 
neovascularization) as well as reparative mechanisms (myocardial fibrosis) and therefore this 
injury-model constitutes a valuable tool to dissect the switch between both mechanisms.  
During neonatal injury response cardiac fibroblasts seem to have a dual role. Hence, 
cardiac fibroblasts are responsible for the production of regeneration-associated proteins 
(e.g. Fn and Tn-C), however at later time-points they acquire a fibrogenic phenotype, 
characterized by the production/deposition of collagen. Hence, further studies are required 
to ascribe the role of the different fibroblast populations following cardiac injury. We have 
established the grounds for the transcriptomic analysis of different cardiac fibroblast subsets 
by FACS-sorting the main populations altered following apex-resection. 
 Overall, the results herein described represent a conciliatory perspective on neonatal 
cardiac response to injury. Both regenerative and reparative mechanisms seem to be 
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activated upon injury, although the regenerative capacity reveals to be insufficient to 
completely restore the neonatal, being overwhelmed by repair.  
 
 
 
Figure 20. Proposed model of neonatal heart injury response. After apex resection, a blood clot is 
formed, initiating the inflammatory response through infiltration of hematopoietic cells. Gradually, ECM 
remodeling occurs by overexpression of Fn and Tn-C, initially associated with hematopoietic cells and 
afterwards with fibroblasts/myofibroblasts. While the microenvironment induces CM migration and 
proliferation from the neighbouring myocardium to the apex, at the central region, where the lumen 
was exposed, cell repopulation is insufficient to re-establish the initial tissue architecture and cardiac 
fibrosis settles.  
 
7.1 - Future Perspectives 
 Albeit the herein MSc thesis incorporates novel insight about the neonatal cardiac 
injury, several experiments are still required to further understand the mechanisms and 
cellular/extracellular dynamics underlying apex resection in neonatal mice (Table 4). 
 Firstly, cardiac function evaluation 60 days post surgery would be a fundamental 
information, clarifying whether the scar expansion, from 21 to 60 days, could impact on heart 
function. Additionally, heart resistance to physical activity could be performed in 60 days-old 
injured mice to access the impact of fibrosis to support daily life activities. Concomitantly, it 
would be interesting to do an electrocardiographic analysis in order to confirm if the sub 
expression of Cx43 is affecting the normal impulse propagation and associated to 
cardiomyopathy.  
 Regarding cardiac fibroblast population, the dissection of different phenotypic 
profiles anticipates distinct performances on the cardiac injury response. In this sense, qPCR 
will be performed, envisioning the association of particular transcriptomic levels with 
populations with regenerative or reparative behavior.  
 Furthermore, to complete CM morphometric analysis, Langendorf–based isolation of 
adult CMs will further confirm the lack of hypertrophic parameters and the phenotype (rod or 
round) of adult CM. Unfortunately, this analysis was not possible during the development of 
the herein MSc thesis once the isolation protocol establish in our lab is not optimized for 
adult CMs. 
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 Although CM proliferation was ascertained in the scope of this work, CM cytokinesis 
would be an important parameter to assess cardiomyocytic repopulation. In this sense, co 
localization of Aurora B kinase (AurB) with a CM marker would answer this purpose. In line 
with this, CM lineage tracing, through genetic fate mapping approach, would be a strategy to 
determine the origin of the new CM within the apex region.  
 A key question that arises from this work is whether CM proliferation is insufficient to 
fully restore the myocardium or if the regenerative mechanisms are halted by cardiac 
fibrosis. Drug administration for blocking TGF-β or inducible tissue-specific knockout for 
upstream targets of fibrosis would be possible approaches. 
 Furthermore, a deeper analysis of the ECM components might be important to design 
useful applications for clinical purposes such as biodegradable cardiac patches or engineer 
biomimetic matrices that promote regeneration rather than a scar-forming response. In this 
sense, primary cultures of CMs and/or cardiac fibroblasts onto different ECM-coated plates 
could give us new insights about proliferation and migration to optimize cardiac repair.  
 
 
Table 4. Future perspectives - proposed aims and strategies.  
Aim Strategy 
Assess cardiac function 60 days 
post-surgery 
Echocardiography; 
electrocardiography and increase 
physical activity 
Dissect the role of cardiac 
fibroblasts population 
qPCR 
Deeper analysis of neomyogenic 
potential 
Imaging flow cytometry of 
Langerdorf isolated CMs and 
immunohistochemistry of AurB 
Ascertain CM origin upon cardiac 
injury 
CM lineage tracing 
Assess the limiting mechanism (CM 
proliferation or fibrosis) 
Inhibition of one of the process in 
vivo 
Understand ECM-mediated cardiac 
cells behaviour in vitro 
CM culture onto different ECM 
coated plates 
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